DOJ Escalates Antitrust Probe Into Claritev, UnitedHealth Group Slips Nearly 1% After Hours

The U.S. Department of Justice’s antitrust probe into healthcare data and analytics firm Claritev is widening, with regulators issuing new information demands to related parties. The development has put UnitedHealth Group (UNH), a key Claritev customer and shareholder, back in the spotlight. As of 4:00 PM ET on July 14, UnitedHealth closed at $425.19, down 0.91% from the prior close of $429.09, after hitting an intraday low of $421.785.^{[Modern Healthcare]}

DOJ Probe Intensifies, Broader Information Demands

According to Modern Healthcare, citing a Bloomberg report from July 14, the DOJ’s investigation into Claritev is “intensifying with new information demands.” The report states that investigators have issued broader information requests to related parties, signaling the antitrust probe has entered a deeper phase. Claritev provides data analytics and cost management services to health insurers and employers, handling medical claims data processing and pricing analysis.^{[Modern Healthcare]}

The escalation comes as the Biden administration continues to ramp up antitrust scrutiny of the healthcare sector, particularly targeting middlemen and data analytics firms. Earlier, the Federal Trade Commission (FTC) filed lawsuits against pharmacy benefit managers (PBMs), accusing them of inflating drug prices through insulin pricing. On July 14, the FTC reached a settlement with CVS Health over the related insulin lawsuit.^{[Modern Healthcare]}

UnitedHealth’s Deep Ties to Claritev

UnitedHealth and Claritev are bound by a complex web of commercial and equity relationships. UnitedHealth’s Optum unit is a major Claritev customer, using its data analytics services to manage healthcare costs. Additionally, UnitedHealth holds a minority stake in Claritev through its venture capital arm. This deep linkage means any adverse findings in the DOJ’s probe into Claritev could have ripple effects on UnitedHealth.

Market analysts note that if the DOJ ultimately finds Claritev engaged in anticompetitive behavior, UnitedHealth could face business adjustments or financial losses. However, the investigation remains in the information-gathering stage, with no formal charges filed yet.^{[Modern Healthcare]}

Stock Under Pressure, Hits Fresh Intraday Low

Shares of UnitedHealth came under clear pressure in today’s session on the news of the probe’s escalation. The stock opened at $431, hit a high of $432.15, then steadily declined to a low of $421.785 before closing at $425.19, down 0.91% from the prior close. The move extends the stock’s recent weakness.

Notably, some institutional investors have already adjusted their UnitedHealth positions. According to InsuranceNewsNet, Ferguson Wellman Capital Management Inc. recently trimmed its stake in the company.^{[InsuranceNewsNet]}

Healthcare Antitrust Scrutiny Tightens

UnitedHealth is not alone in facing regulatory headwinds. The DOJ and FTC have significantly stepped up antitrust enforcement across the healthcare sector. Beyond the Claritev probe, the DOJ is investigating other healthcare data firms and has also launched a probe into allegations surrounding the president of the United Auto Workers (UAW).^[Reuters]

In the broader healthcare arena, the FTC’s settlement with CVS Health over the insulin pricing lawsuit marks a milestone in the crackdown on PBMs. Separately, Alignment Healthcare (ALHC) is facing investor lawsuits after a former executive alleged “accounting irregularities,” sending its stock down 16.7% in a single day on July 8.^{[NewMediaWire]}

These cases underscore that regulators are tightening the screws on the healthcare industry from multiple angles. For a giant like UnitedHealth, every business link is now under the regulatory microscope.

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.